164 related articles for article (PubMed ID: 36508196)
1. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C.
Ogawa E; Chien N; Kam L; Yeo YH; Ji F; Huang DQ; Cheung R; Nguyen MH
JAMA Intern Med; 2023 Feb; 183(2):97-105. PubMed ID: 36508196
[TBL] [Abstract][Full Text] [Related]
2. Treatment rates and factors associated with direct-acting antiviral therapy for insured patients with hepatitis C-related hepatocellular carcinoma - A real-world nationwide study.
Kam LY; Yeo YH; Ji F; Henry L; Cheung R; Nguyen MH
Aliment Pharmacol Ther; 2024 Feb; 59(3):350-360. PubMed ID: 37937485
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study.
Choi GH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Jang JW; Ki M; Choi HY; Baik D; Jeong SH
World J Gastroenterol; 2022 Aug; 28(30):4182-4200. PubMed ID: 36157119
[TBL] [Abstract][Full Text] [Related]
4. Impact of Direct-acting Antivirals on Hepatocellular Carcinoma and Mortality Among Medicaid Beneficiaries With Hepatitis C.
Jiang X; Song HJ; Chang CY; Wilson DL; Lo-Ciganic WH; Park H
Med Care; 2023 Aug; 61(8):505-513. PubMed ID: 37223993
[TBL] [Abstract][Full Text] [Related]
5. Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis.
Yew KC; Tan QR; Lim PC; Low WY; Lee CY
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1421-1431. PubMed ID: 37728622
[TBL] [Abstract][Full Text] [Related]
6. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
7. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
8. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
[TBL] [Abstract][Full Text] [Related]
10. Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C.
McGlynn EA; Adams JL; Kramer J; Sahota AK; Silverberg MJ; Shenkman E; Nelson DR
JAMA Netw Open; 2019 Jun; 2(6):e194765. PubMed ID: 31173117
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
12. Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis.
Sahakyan Y; Lee-Kim V; Bremner KE; Bielecki JM; Krahn MD
J Viral Hepat; 2021 May; 28(5):739-754. PubMed ID: 33556225
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.
Wong YJ; Tran S; Huang CF; Hsu YC; Preda C; Toyoda H; Liu J; Jun DW; Landis C; Huang DQ; Gila A; Negoita L; Yasuda S; Tseng CH; Tsai PC; Uojima H; Nozaki A; Chuma M; Atsukawa M; Ishigami M; Itokawa N; Iio E; Lam CP; Watanabe T; Asai A; Yokohama K; Abe H; Enomoto M; Kawada N; Tamori A; Lee DH; Jun MJ; Do S; Vo DKH; Liu L; Li J; Ji F; Wang W; Li Y; Wang X; Guo F; Xu Q; Jing L; Ye Q; Pan H; Zhang J; Wen X; Wang Q; Ren H; Cai D; Shang J; Liu J; Lu C; Zang W; Li J; Niu J; Zhang M; Wu C; Huang R; Maeda M; Nakanishi A; Yeh ML; Chuang WL; Huang JF; Dai C; Ishikawa T; Takaguchi K; Senoh T; Trinh HN; Takahashi H; Eguchi Y; Quek SXZ; Haga H; Ogawa E; Wong G; Buti M; Fukunishi S; Ueno Y; Yuen MF; Tanaka Y; Lim SG; Cheung R; Yu ML; Nguyen MH
Hepatol Int; 2023 Oct; 17(5):1150-1161. PubMed ID: 37273170
[TBL] [Abstract][Full Text] [Related]
15. Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study.
Hyun HK; Cho EJ; Park SY; Hong YM; Kim SS; Kim HY; Heo NY; Park JG; Sinn DH; Kang W; Jeong SW; Song MJ; Park H; Lee D; Lee YS; Cho SB; An CS; Rhee HJ; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee JH; Yu SJ; Kim YJ; Yoon JH; Tak WY; Kweon YO; Yoon KT; Cho M; Cheong JY; Park SH; Kim SU;
Dig Dis Sci; 2021 Jul; 66(7):2427-2438. PubMed ID: 32856240
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C.
Benhammou JN; Moon AM; Pisegna JR; Su F; Vutien P; Moylan CA; Ioannou GN
Dig Dis Sci; 2021 Jul; 66(7):2394-2406. PubMed ID: 32654086
[TBL] [Abstract][Full Text] [Related]
17. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
McDonald SA; Pollock KG; Barclay ST; Goldberg DJ; Bathgate A; Bramley P; Dillon JF; Fraser A; Innes HA; Kennedy N; Morris J; Went A; Hayes PC; Hutchinson SJ
J Viral Hepat; 2020 Mar; 27(3):270-280. PubMed ID: 31696575
[TBL] [Abstract][Full Text] [Related]
18. Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C.
Kalidindi Y; Jung J; Feldman R; Riley T
JAMA Netw Open; 2020 Jul; 3(7):e2011055. PubMed ID: 32692371
[TBL] [Abstract][Full Text] [Related]
19. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
[TBL] [Abstract][Full Text] [Related]
20. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
Singal AG; Rich NE; Mehta N; Branch A; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Wong R; Huang A; Misra S; Schwartz M; Mitrani R; Nakka S; Noureddine W; Ho C; Konjeti VR; Dao A; Nelson K; Delarosa K; Rahim U; Mavuram M; Xie JJ; Murphy CC; Parikh ND
Gastroenterology; 2019 May; 156(6):1683-1692.e1. PubMed ID: 30660729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
